Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

TPP and IP: The Economic Benefits of a Pacific Trade Agreement


Ndp Analytics recently published a study on the economic benefits of intellectual property rights (IP) in the Trans-Pacific Partnership. They find that 2/3’s of the “economic benefits for the U.S. economy and the 11 partner countries would come from IP-intensive manufacturing industries.” They conclude that “the stronger the protection of IP rights under the TPP, the greater the value of trade leading to greater economic growth, additional jobs created, higher incomes, and development across countries.” Here Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Patently Biotech’s Top Articles of 2013


Intellectual property featured prominently in 2013’s public discourse. Gene patents, patent trolls, India’s anti-patent actions, and other developments around the world captured headlines. Here are Patently Biotech’s top blog posts written in 2013 by number of views. 1.   Myriad Supreme Court Decision: BIO’s Statement 2.  Kirtsaeng v. John Wiley & Sons: No Good Deed Goes Unpunished 3.  What a Patent is Not 4.  Gene Patents, Angelina Jolie, and Reality 5.  What OxyContin Tells Us About Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

TRIPs Has Delivered: Patent Agreement Increases Drug Development

US Patent Application

The TRIPs (Trade Related Aspects of Intellectual Property) Agreement, effective in 1996, has resulted in multiple benefits for public health. The last blog post reviewed Progressive Economy’s finding of TRIPS at 20. One additional benefit not mentioned in the article is the explosion of molecules in clinical development. The World Intellectual Property Indicators – 2012 Edition reveals an overall growth in patent applications around the world. The report finds that patent applications “worldwide doubled from Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patents Improve Public Health: Progressive Economy Reviews TRIPS at 20 Years

flags with blue sky

Progressive Economy released a research paper examining the effect of TRIPS (Trade-Related Aspects of Intellectual Property) on global health. Here are their findings quoted from their press release: “1. Since the TRIPS agreement went into effect on New Year’s Day 1995, research and development spending has risen significantly worldwide (relative to the size of GDP). For OECD members, the rise is from 2.1 percent to 2.4 percent of GDP, or in practice an additional $220 Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Neglected Diseases: What if IP was the Cure?

science lab

The Lancet Global Health Journal recently published an article “The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment” discussing the current research and development ongoing in this area.  They found 1,500 clinical trials were registered for neglected diseases which represents only 1% of all registered clinical trial activity.  Of the 123 new products in development for neglected disease, more than half were vaccines or biological products.  However, the article points out that Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , ,